立即加载植入物的转换假体的临床结果:一项回顾性研究
Karolina M Migus1, Avinash S Bidra1, Chia-Ling Kuo2
1Department of Prosthodontics, University of Connecticut Health Center, Farmington, Connecticut, USA.
概括
这项研究表明,用于立即加载的烯酸树脂完整门固定植入物支持假体 (CAFIP) 的假牙转换协议具有很高的生存率 (植入物为98%,假体为94%). 这种基于证据的技术可以预测即时植入物加载.
科学领域:
- 牙科植入物学 牙科植入物学
- 牙修复 牙修复 牙修复 牙修复 牙修复
- 在牙科的材料科学.
背景情况:
- 牙科植入物的即时加载为患者治疗时间表提供了潜在的好处.
- 假牙转换协议提供了一种方法,可以从现有的假牙制造出植入式假牙.
- 评估这些假肢的生存率和并发症率对于临床采用至关重要.
研究的目的:
- 评估使用假牙转换协议创建的立即加载的烯酸树脂完整门固定植入物支持假肢 (CAFIP) 的生存结果.
- 确定与这些假肢相关的牙科植入物的早期存活率.
主要方法:
- 对117名患者进行了回顾性图表审查,这些患者在9年内通过假牙转换协议接受了CAFIP即时加载的烯酸树脂.
- 收集的数据包括植入失败,假肢骨折,技术并发症和对立牙.
- 进行了统计分析,显著度为p < 0.05.
主要成果:
- 评估了153个假肢和768个植入物,植入物存活率为98%,假肢在4个月内无并发症存活率为94.1%.
- 早期的关键假肢并发症 (骨折) 发生在9种假肢中 (5.9%),上和下弓之间有统计学上显著的差异 (p=0.037).
- 在愈合期间,只有3种植入失败与假肢失败有关.
结论:
- 假牙转换协议显示,牙科植入物 (98%) 和立即加载假肢 (94%) 的早期生存率很高.
- 该协议是一种简单的,基于证据的,可预测的方法,可以立即加载植入物.
- 通过这种技术观察到最小的植入失败和非关键并发症.
更多相关视频
06:58A Structured Rehabilitation Protocol for Improved Multifunctional Prosthetic Control: A Case Study
Published on: November 6, 2015
9.4K
09:51The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve
Published on: September 7, 2022
2.5K
相关概念视频
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...